943
Participants
Start Date
November 16, 2015
Primary Completion Date
October 10, 2016
Study Completion Date
January 11, 2017
SOF/VEL/VOX
400/100/100 mg tablet administered orally once daily with food
SOF/VEL
400/100 mg tablet administered orally once daily with or without food
Long Beach
Los Angeles
Palo Alto
Pasadena
Rialto
San Diego
San Francisco
Aurora
Englewood
Washington D.C.
Gainesville
Miami
Orlando
Wellington
Atlanta
Marietta
Chicago
Indianapolis
Bastrop
Baltimore
Catonsville
Boston
Ann Arbor
Detroit
Kansas City
St Louis
Hillsborough
Manhasset
New York
The Bronx
Asheville
Fayetteville
Philadelphia
Pittsburgh
Providence
Germantown
Knoxville
Nashville
Houston
Live Oak
San Antonio
Murray
Falls Church
Norfolk
Richmond
Seattle
Madison
Darlinghurst
Herston
Fitzroy
Melbourne
Perth
Calgary
Edmonton
Vancouver
Brampton
Ottawa
Toronto
Montreal
Bobigny
Clermont-Ferrand
Clichy
Créteil
Grenoble
Lille
Limoges
Lyon
Marseille
Montpellier
Nice
Orléans
Paris
Pessac
Rennes
Rouen
Strasbourg
Toulouse
Vandœuvre-lès-Nancy
Villejuif
Berlin
Bonn
Cologne
Frankfurt am Main
Hamburg
Hanover
Christchurch
Grafton
San Juan
London
Manchester
Nottingham
Oxford
Portsmouth
Lead Sponsor
Gilead Sciences
INDUSTRY